Many significantly scored mutations were involved in pathways previously determined to impact endometrial cancer, e.g. PI3K, Wnt signalling, MAPK signalling and p53 signalling pathways (Kanehisa et al., 2012). This evidence concerns the gene TP53 and endometrial cancer.